Transdermal fentanyl in cancer pain.
Where this comes from
- Record sourced from PubMed, PMID 1575123.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Transdermal fentanyl appears to be a safe and practical alternative to short-acting analgesics in the treatment of cancer pain. The unique pharmacokinetics of the transdermal system, including the prolonged time to peak analgesic effect, long elimination half-life and skin depot concept, should be kept in mind when prescribing the system. Short-acting narcotics are recommended for break-through pain. Side effects of fentanyl, and their management, are similar to those associated with other narcotic analgesics.